Department of Oncology, Pain and Palliative Care Research Unit, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
Department of Oncology, Laboratory of Methodology for Clinical Research, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, 20156, Milan, Italy.
Adv Ther. 2021 Aug;38(8):4289-4303. doi: 10.1007/s12325-021-01814-7. Epub 2021 Jul 6.
Delirium occurs in 50-80% of end-of-life patients but is often misdiagnosed. Identification of clinical factors potentially associated with delirium onset can lead to a correct early diagnosis. To this aim, we conducted a prospective cohort study on patients from an Italian palliative care unit (PCU) admitted in 2018-2019. We evaluated the presence of several clinical factors at patient admission and compared their presence in patients who developed delirium and in those who did not develop it during follow-up. Among 503 enrolled patients, after a median follow-up time of 16 days (interquartile range 6-40 days), 95 (18.9%) developed delirium. Hazard ratios (HR) and corresponding 95% confidence intervals were computed using Cox proportional hazard models. In univariate analyses, factors significantly more frequent in patients with delirium were care in hospice, compromised performance status, kidney disease, fever, renal failure, hypoxia, dehydration, drowsiness, poor well-being, breathlessness, and "around the clock" therapy with psychoactive drugs, particularly haloperidol. In multivariate analyses, setting of care (HR 2.28 for hospice versus home care, 95% CI 1.45-3.60; p < 0.001), presence of breathlessness (HR 1.71, 95% CI 1.03-2.83, p = 0.037), and administration of psychoactive drugs, particularly haloperidol (HR 2.17 for haloperidol, 95% CI 1.11-4.22 and 1.53 for other drugs, 95% CI 0.94-2.48; p = 0.048) were significantly associated with the risk of developing delirium. The study indicates that some clinical factors are associated with the probability of delirium onset. Their evaluation in PC patients could help healthcare professionals to identify the development of delirium in those patients in a timely manner.
谵妄发生于 50%-80%的终末期患者中,但常常被误诊。识别与谵妄发作相关的临床因素可能有助于早期正确诊断。为此,我们对 2018 年至 2019 年期间入住意大利姑息治疗病房(PCU)的患者进行了一项前瞻性队列研究。我们评估了患者入院时的多种临床因素,并比较了在随访期间发生和未发生谵妄的患者中这些因素的存在情况。在纳入的 503 例患者中,中位随访时间为 16 天(四分位间距 6-40 天),95 例(18.9%)发生谵妄。使用 Cox 比例风险模型计算危险比(HR)及其相应的 95%置信区间。在单因素分析中,谵妄患者更常见的因素是在临终关怀机构接受治疗、功能状态受损、肾脏疾病、发热、肾衰竭、缺氧、脱水、嗜睡、身体不适、呼吸困难,以及“全天候”使用精神活性药物治疗,尤其是氟哌啶醇。在多因素分析中,治疗场所(临终关怀机构与家庭护理相比,HR 为 2.28,95%CI 为 1.45-3.60;p<0.001)、存在呼吸困难(HR 为 1.71,95%CI 为 1.03-2.83,p=0.037)以及使用精神活性药物,特别是氟哌啶醇(氟哌啶醇的 HR 为 2.17,95%CI 为 1.11-4.22,其他药物的 HR 为 1.53,95%CI 为 0.94-2.48;p=0.048)与发生谵妄的风险显著相关。该研究表明,一些临床因素与谵妄发作的可能性相关。在 PC 患者中评估这些因素可能有助于医疗保健专业人员及时识别那些患者发生谵妄的情况。